Stockreport

Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

Royalty Pharma plc - Class A Ordinary Shares  (RPRX) 
US:NASDAQ Investor Relations: ir.reprosrx.com/investor-relations
PDF Royalty Pharma to provide tailored funding solution to enable MorphoSys’ acquisition of Constellation PharmaceuticalsInvestment is anchored by royalties on Janssen’s Tre [Read more]